EssexBio

Essex-Bio Group

简繁 EN

COMPANY NEWS

Essex Bio-Technology establishes strategic collaboration with Biosparc Signs MOU with SIPIPO and Biosparc on International Innovation Accelerator

2025.11.21

Essex Bio-Technology (1061.HK) 2025 Interim Results at a glance

2025.08.26

Resilient Interim Results: Essex Bio-Technology Drives Growth and Innovation, Revenue up 5.8% to HK$876.5 Million, Profit up 3.8% to HK$ 163.4 million, 16.7% Dividend Surge, Continued Innovation Momentum in Regulatory Milestones

2025.08.26

Date

Title

2024-01-03

Change of Address of Head Office and Principal Place of Business in Hong Kong

2023-08-16

Essex Bio-Technology (1061.HK) 2023 Interim Results at a glance

2023-08-16

Essex Bio-Technology Posts Sound 2023 Interim Financial Results Revenue Up 37.1%, Profit Up 22%

2023-07-26

The phase 1/2 clinical trial of Bevacizumab for treatment of Ophthalmic Diseases completed

2023-06-30

EssexBio awarded “2022 China Pharmaceutical Industry Top 100 Series List” and “2023 China Pharmaceutical Brands List”

2023-04-14

Essex and Osteopore Entered into Exclusive Distribution Agreement for Oral Maxillofacial products in Singapore

2023-04-11

Essex and Gunze Shenzhen Entered into Exclusive Agency Agreement for PELNAC® Absorbable Dressing in Mainland China

2023-03-08

Essex Bio-Technology (1061.HK) 2022 Annual Results at a glance

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

ACCEPT